Q2 Earnings Forecast for AVBP Issued By Lifesci Capital

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Analysts at Lifesci Capital issued their Q2 2025 EPS estimates for ArriVent BioPharma in a note issued to investors on Monday, June 23rd. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings of ($0.75) per share for the quarter. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma's Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.66) EPS.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($1.24).

AVBP has been the topic of several other research reports. HC Wainwright increased their price target on shares of ArriVent BioPharma from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Jones Trading initiated coverage on shares of ArriVent BioPharma in a report on Tuesday, May 20th. They issued a "buy" rating and a $40.00 price objective on the stock. B. Riley began coverage on shares of ArriVent BioPharma in a research note on Thursday, March 20th. They issued a "buy" rating and a $37.00 price objective on the stock. Oppenheimer boosted their target price on shares of ArriVent BioPharma from $39.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday. Finally, Guggenheim reaffirmed a "buy" rating and issued a $45.00 price target on shares of ArriVent BioPharma in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.00.

ArriVent BioPharma Stock Up 1.4%

Shares of NASDAQ:AVBP opened at $23.11 on Wednesday. ArriVent BioPharma has a 52-week low of $15.47 and a 52-week high of $36.37. The stock has a market cap of $790.66 million, a price-to-earnings ratio of -6.13 and a beta of 1.26. The business has a 50-day moving average price of $21.37 and a 200-day moving average price of $23.07.

Hedge Funds Weigh In On ArriVent BioPharma

Several large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its holdings in ArriVent BioPharma by 773.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,599 shares of the company's stock valued at $43,000 after buying an additional 1,416 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of ArriVent BioPharma during the 4th quarter valued at about $73,000. KLP Kapitalforvaltning AS purchased a new position in shares of ArriVent BioPharma in the 4th quarter valued at about $83,000. Jane Street Group LLC purchased a new position in shares of ArriVent BioPharma in the 1st quarter valued at about $189,000. Finally, New York State Common Retirement Fund raised its holdings in ArriVent BioPharma by 34.6% in the 4th quarter. New York State Common Retirement Fund now owns 7,783 shares of the company's stock worth $207,000 after purchasing an additional 2,000 shares during the period. 9.48% of the stock is currently owned by institutional investors and hedge funds.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.